STOCKWATCH
·
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Quarterly ResultApr 13, 2026, 05:21 PM

BIOMERICA Cash & Equivalents Drop to $1.34M in Q3 FY2026

AI Summary

BIOMERICA, Inc. filed its Form 10-Q for the quarter ended February 28, 2026. The company reported cash and cash equivalents of $1,336,000 as of February 28, 2026. This represents a decrease from $2,399,000 reported on May 31, 2025, indicating a significant reduction in its cash position over the nine-month period.

Key Highlights

  • Cash and cash equivalents at $1,336,000 as of Feb 28, 2026.
  • Cash decreased from $2,399,000 reported on May 31, 2025.
  • Quarterly report filed for period ended February 28, 2026.
BMRA
Biotechnology: In Vitro & In Vivo Diagnostic Substances
BIOMERICA INC

Price Impact